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Posttreatment Antifungal Resistance among Colonizing Candida
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R. H. Jensen,a H. K. Johansen,b L. M. Søes,c,d L. E. Lemming,e F. S. Rosenvinge,f,g L. Nielsen,h B. Olesen,i L. Kristensen,j,k E. Dzajic,l
K. M. T. Astvad,a M. C. Arendrupa
Unit of Mycology, Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmarka; Department of Clinical Microbiology,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmarkb; Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre,
Denmarkc; Department of Clinical Microbiology, Slagelse Sygehus, Slagelse, Denmarkd; Department of Clinical Microbiology, Aarhus University Hospital, Aarhus,
Denmarke; Department of Clinical Microbiology, Sygehus Lillebælt, Vejle, Denmarkf; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmarkg;
Department of Clinical Microbiology, Herlev University Hospital, Herlev, Denmarkh; Department of Clinical Microbiology, Nordsjællands Hospital, Hillerød, Denmarki; Department
of Clinical Microbiology, Hospitalsenheden Vest, Herning, Denmarkj; Department of Clinical Microbiology, HospitalsenhedenMidt, Viborg, Denmarkk; Department of Clinical
Microbiology, Sydvestjysk Sygehus, Esbjerg, Denmarkl
The prevalence of intrinsic and acquired resistance among colonizing Candida isolates from patients after candidemia was in-
vestigated systematically in a 1-year nationwide study. Patients were treated at the discretion of the treating physician. Oral
swabs were obtained after treatment. Species distributions andMIC data were investigated for blood and posttreatment oral
isolates from patients exposed to either azoles or echinocandins for<7 or>7 days. Species identification was confirmed using
matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOFMS) and internal transcribed spacer
(ITS) sequencing, susceptibility was examined by EUCAST EDef 7.2 methodology, echinocandin resistance was examined by FKS
sequencing, and genetic relatedness was examined bymultilocus sequence typing (MLST). One hundred ninety-three episodes
provided 205 blood and 220 oral isolates. MLST analysis demonstrated a genetic relationship for 90% of all paired blood and oral
isolates. Patients exposed to azoles for>7 days (n 93) had a significantly larger proportion of species intrinsically less suscep-
tible to azoles (particularly Candida glabrata) among oral isolates than among initial blood isolates (36.6% versus 12.9%; P<
0.001). A similar shift toward species less susceptible to echinocandins among 85 patients exposed to echinocandins for>7 days
was not observed (4.8% of oral isolates versus 3.2% of blood isolates; P> 0.5). Acquired resistance in Candida albicanswas rare
(<5%). However, acquired resistance to fluconazole (29.4%; P< 0.05) and anidulafungin (21.6%; P< 0.05) was common in C.
glabrata isolates from patients exposed to either azoles or echinocandins. Our findings suggest that the colonizing mucosal mi-
crobiota may be an unrecognized reservoir of resistant Candida species, especially C. glabrata, following treatment for candi-
demia. The resistance rates were high, raising concern in general for patients exposed to antifungal drugs.
Candidemia due to Candida species which are intrinsically lesssusceptible to fluconazole is becoming proportionally more
common at the expense of Candida albicans (1–5). Prophylactic
antifungal use has been demonstrated to significantly drive the
species distributions in candidemia patients toward less suscepti-
ble species, such as Candida glabrata in patients exposed to flu-
conazole and Candida parapsilosis in patients exposed to caspo-
fungin (6–8). Indeed, intrinsic resistance and the changing
epidemiology are themain concerns. On the other hand, acquired
resistance is rare in epidemiologic candidemia studies, perhaps in
part because such studies include only the initial blood isolate
from each candidemia patient. Thus, subsequent and potentially
resistant isolates may be overlooked. Resistance selection may be
facilitated by a longer duration of treatment (9) and subtherapeu-
tic drug levels (10, 11). Hence, abdominal candidiasis and Can-
dida species atmucosal surfacesmay represent a nest and reservoir
for resistant isolates (10, 12). Typing studies have illustrated that
the concomitant and predominant colonizing Candida isolate in
candidemia patients is also the invasive Candida species (90 to
95% concordance), and most patients are still colonized despite
the infection being cleared (7, 9, 13–17). Thus, the persistent col-
onizing microbiota is a relevant reservoir for resistant Candida
strains andmay impose a risk to this group of patients concerning
reinfection, but also to individuals in other patient settings, where
infection may follow prior antifungal drug exposure. The present
study was a systematic nationwidemulticenter study investigating
the colonizing microbiota obtained in candidemia patients after
antifungal drug exposure. The purpose was to elucidate the prev-
alence of Candida species less susceptible to antifungals and the
extent of acquired resistance in the colonizing mucosal microbi-
ota of patients treated for candidemia, since the increasing num-
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ber of reports addressing these topics includesmainly case reports
or single-center studies (18).
MATERIALS AND METHODS
Patients, isolates, and treatment. All candidemia patients in Denmark
diagnosed within the 1-year study period (March 2013 to February 2014)
were eligible for inclusion in this study. Blood isolates were referred to the
Mycology Reference Laboratory at Statens Serum Institut as part of the
ongoing national surveillance of fungemia fromall departments of clinical
microbiology in Denmark. Corresponding candidemia patients were lo-
cated through the Danish Microbiology Database (MiBa), and one oral
swab was requested after discontinuation of antifungal treatment. Sepa-
rate candidemia episodes were included only if they occurred 21 days
apart. Information on antifungal treatment for invasive candidiasis (IC)
but not empirical treatment was sought. Patients were excluded if an oral
swab or IC treatment information was not obtained.
Prevalence of intrinsic resistance. For patients (n 93) treated with
azoles for 7 days but with a drug from another drug class for 7 days
(Fig. 1), species distributions in blood isolates (before IC treatment) and
oral isolates (after IC treatment) were determined, and the proportions of
species intrinsically less susceptible to azoles were compared. Likewise, for
patients (n 62) treated with echinocandins for7 days but with a drug
from another drug class for 7 days (Fig. 1), the proportions of species
intrinsically less susceptible to echinocandins among blood and oral iso-
lates were compared. The 7-day cutoff for significant exposure was se-
lected based on previous findings identifying this duration as a critical
driver of altered species distribution (9). Because coadministration of
different drug classes (combination or sequential) for7 days might bias
the evaluation of each drug class’s impact on posttreatment species distri-
bution, patients undergoing such coadministration (n  26) were ex-
cluded from this evaluation.
Species-specific prevalence of acquired resistance. Rates of acquired
resistance among initial blood and posttreatment oral isolates were eval-
uated for C. albicans and C. glabrata isolates. Susceptibility data for oral
isolates from patients exposed to either azoles (n 114; 109/114 patients
exposed to fluconazole and 5/114 exposed to voriconazole) or echinocan-
dins (n 85) for7 days were evaluated for both species. Susceptibility
data for blood isolates as well as oral isolates exposed to either azoles (n
79) or echinocandins (n 108), respectively, for7 days were included
for both species for comparison. Coadministration of unrelated drug
classes was not regarded as a driver of acquired resistance. Therefore, the
evaluation of acquired resistance to a given drug class included all pa-
tients, with and without exposure to alternative drug classes.
Ethical considerations.This studywas approved by the Research Eth-
ics Committees of the Capital Region of Denmark (protocol no. H-4-
2012-FSP 104), the Danish Data Protection Agency (protocol no. 2013-
41-1606), and the Danish Health and Medicines Authority (protocol no.
3-3013-302/1/).
Microbiology. Blood isolates and oral swabs were inoculated onto
CHROMagar (CHROMagar Co., Paris, France) for 2 to 4 days at 37°C.
Species identifications were done by conventional methods and matrix-
assisted laser desorption ionization–time of flight mass spectrometry
(MALDI-TOFMS) analysis (Bruker Daltonics, Germany), supplemented
with carbon assimilation with ATB strips (ID32C; bioMérieux, Marcy
l’Etoile, France) or internal transcribed spacer (ITS) DNA sequencing
when necessary (19). Polyfungal samples were identified by colony color
differentiation (also within the same species) and separated by subcultur-
ing. Isolates were considered to be unique if a different species was de-
tected or if the same species had different genotypes or susceptibility pro-
files (2-fold dilution MIC difference of 3 for any antifungal tested).
MiBa was further used to assess microbiological data.
Susceptibility testing was done according to EUCAST EDef 7.2 (azoles
and anidulafungin) (20) and by Etest (amphotericin B). Susceptibility
interpretation was performed by applying the defined EUCAST break-
points (21, 22; http://www.eucast.org/clinical_breakpoints/).
Statistical analyses. Species distributions were compared by unpaired
proportion analyses (chi-square tests). Candida krusei, C. glabrata, Can-
dida guilliermondii, Candida pelliculosa, Saccharomyces cerevisiae, and
Cryptococcus neoformanswere classified as species intrinsically less suscep-
tible to azoles. Similarly,C. parapsilosis,C. guilliermondii, and S. cerevisiae
were classified as less susceptible to the echinocandins. S. cerevisiae was
regarded as less susceptible to both drug classes because the modalMIC is
comparable to that for C. glabrata for azoles (EUCAST data) but at least
one step higher for echinocandins (unpublished data). When multiple
species were found in blood or swabs, the isolate of the species with the
highest epidemiological cutoff value (ECOFF) was counted. Numbers of
FIG 1 Flowchart illustrating the numbers of eligible patients, included patients, and episodes, divided into those for patients receiving7 days of exposure to
azoles (93), echinocandins (62), polyenes (7), or a combination thereof (26). The total numbers of episodes for patients exposed to azoles, echinocandins, and
polyenes for7 days (irrespective of sequential or concomitant additional treatment) were 114, 85, and 16, respectively.
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negative oral cultures or polyfungal oral cultures were compared as a
subanalysis between patients exposed to either azoles or echinocandins to
determine the degree of fungal colonization after antifungal exposure.
Fisher’s exact test of unpaired data was applied to compare propor-
tions of acquired resistance among C. albicans and C. glabrata isolates
from blood and oral swabs from patients exposed to an antifungal for7
days or7 days. The difference inmeanMICs for each drug class was also
determined for C. glabrata and C. albicans and analyzed by the Wilcoxon
rank sum test, assuming a nonnormal distribution of MIC data. All poly-
fungal isolates were included in these analyses.
All P values of0.05 were considered significant. R software was used
for all statistical calculations.
MLST. Multilocus sequence typing (MLST) was performed as previ-
ously described for the six major species C. albicans (23), C. glabrata (24),
C. krusei (25), Candida tropicalis (26), Candida dubliniensis (27), and S.
cerevisiae (28), and microsatellite typing was used for C. parapsilosis (29).
MLST profiles were assigned according to corresponding pubMLST da-
tabases, when available, or assigned as novel for S. cerevisiae, starting from
“1” for each allele. CLC Main Workbench (CLC-Bio, Qiagen) bioinfor-
matics software with the MLST plug-in was applied to analyze sequence
data. One allelic difference were considered microevolution between
paired isolates, based on previous findings, and thus isolates were re-
garded as genetically unrelated if they differed at two ormore alleles for all
MLST schemes (30, 31).
Resistance mechanisms. Underlying molecular resistance mecha-
nismswere characterized for echinocandin resistance by sequencing of the
gene encoding -1,3-glucan synthase (FKS1).
RESULTS
Demographics.During the 1-year study period, 471 unique blood
isolates from 455 candidemia cases were referred to the reference
laboratory. Oral swabs were obtained from 200 of these patients
from all 12 major hospitals in Denmark; 63 (31.5%) were from
intensive care units (ICUs), 55 (27.5%) from surgical units, 73
(36.5%) from medical units, and 9 (4.5%) from other units. In
total, 194 of 455 patients (42.6%) deceased before the swab was
obtained, and thus 76.6% (200 of 261 patients) of all eligible can-
didemia patients were included (Fig. 1). The remaining 61 pa-
tients were discharged before amouth swabwas obtained. Neither
median age (67 versus 68 years) nor the proportion ofmen (59.6%
versus 57.7%) varied significantly between enrolled patients and
the total population of candidemia patients. Due to insufficient
treatment information, seven patients were excluded. In total, 190
patients (including one neonate) and 193 episodes provided 205
blood isolates and 220 swab isolates included for statistical analy-
ses. The total IC treatmentmedian duration (range)was 17 days (5
to 61 days). The duration of the individual drug class for patients
treatedwith azoles or echinocandins separately for7 dayswas 14
days (7 to 40 days) for azoles and 15 days (7 to 56 days) for echi-
nocandins.
Species distributions. The species distribution among blood
isolates from included patients was similar to the distribution for
all candidemia cases (Fig. 2). Among 93 patients treated with
azoles for 7 days but with another drug class for 7 days, 66
(71.0%) hadC. albicans in the original blood culture, while among
the 62 patients treated with echinocandins for 7 days and with
another drug class for7 days, 41 (66.1%) had C. glabrata in the
blood (Fig. 2). In azole-exposed patients, the species distributions
of blood and oral isolates were significantly different, with 71.0%
of blood isolates being C. albicans and fewer than 20% of oral
isolates being C. albicans (Fig. 2). On the other hand, C. glabrata
and S. cerevisiae constituted about 10% and 1%, respectively, of
blood isolates but about 25% and 7.5%, respectively, of oral iso-
lates. The overall number of isolates less susceptible to fluconazole
was significantly larger (P  0.001) for the oral isolates (34/93
isolates [36.6%]) than for the blood isolates (12/93 isolates
[19.9%]). For the echinocandin group, minor differences were
observed in comparing species distributions among blood and
oral isolates from exposed patients, with smaller proportions ofC.
albicans and C. glabrata observed in the oral isolates. Only 2
(3.2%) isolates categorized as intrinsically less susceptible to echi-
nocandins were found among the blood isolates (1 C. parapsilosis
and 1 Geotrichum candidum isolate), in contrast to three (4.8%)
(1 C. parapsilosis, 1 C. guilliermondii, and 1 S. cerevisiae isolate)
among the oral isolates.
Among patients treated with echinocandins, 87% (54/62 pa-
tients) had culture-positive oral swabs and 63% (39/62 patients)
had polyclonal colonization, compared to 57% (53/93 patients)
and 31% (29/93 patients), respectively, of patients treated with
azoles. Both proportions of culture-positive oral swabs and poly-
clonal colonization were significantly higher in the echinocandin
group (P 0.001 and P 0.001, respectively).
MLST analyses. Among 193 patients, 104 (53.9%) patients
harbored a total of 112 paired isolates, with the same species found
before and after antifungal exposure, 32 patients (16.5%) had a
different colonizing species posttreatment, 57 patients (29.5%)
were swab culture negative, and 72 patients (37.3%) had two or
more isolates in the oral samples. Only 43/100 (43%) patients with
C. albicans in the bloodwere colonizedwithC. albicans after treat-
ment, two patients with C. albicans in the blood had two different
C. albicans isolates in the oral sample, and one patient with two
separate C. glabrata candidemia episodes had C. albicans in both
oral swabs taken 10 weeks apart (see Table S1 in the supplemental
material). Among the total of 45 pairedC. albicans isolates, MLST
analysis showed that 38 (84.4%) had similar genotypes. Similarly,
52 of 62 (83.9%) patients with C. glabrata were colonized with C.
glabrata after treatment, four C. glabrata patients had two differ-
ent C. glabrata isolates in the oral sample, and among a total of 56
paired C. glabrata isolates, 55 (98%) had similar genotypes. Over-
all, 101/112 (90%) paired Candida isolates had similar genotypes
(Table 1; see Table S1).
Susceptibility and resistance. Fluconazole MIC distributions
for the 62 blood and 82 oralC. glabrata isolateswere bimodal, with
peaks at 2 to 4 mg/liter and 32 to 64 mg/liter (Fig. 3). The propor-
tion of resistant isolates (MICs of32 mg/liter) was significantly
higher among oral isolates from azole-exposed patients (29.4%)
than among initial blood isolates (4.8%) (P 0.01) as well as oral
isolates from less exposed patients (10.4%) (P 0.05) (Table 2).
Accordingly, the geometric mean MIC of fluconazole was signifi-
cantly higher for isolates from azole-exposed patients (Table 2). A
similar trend was observed for voriconazole MIC distributions,
although no clinical breakpoint has yet been established for C.
glabrata (Fig. 3). For anidulafungin, the modal MIC was 0.06 mg/
liter, and again, the proportion of isolates with MICs above the
breakpoint was significantly higher among oral isolates from pa-
tients exposed to echinocandins (21.6%) than among blood and
oral isolates from patients exposed to echinocandins for7 days
(4.8% and 3.2%, respectively) (Table 2). No statistical differences
were observed in comparing geometric means (Table 2). Among
the 11C. glabrata isolates (21.6%)with anidulafunginMICs above
the breakpoint (Table 2), three isolates carried wild-type FKS
(with an anidulafunginMICof 0.125mg/liter), while eight isolates
Jensen et al.
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harbored well-known mutations responsible for the observed re-
sistance (MICs of 0.125 to1mg/liter) (Fig. 3).MicafunginMICs
were above the breakpoint for six oral isolates from patients ex-
posed to echinocandins, all six of which harbored FKSmutations.
For twoFKSmutants (F659L and F659I), themicafunginMICwas
below the breakpoint (0.015 mg/liter for both). Two C. glabrata
isolates from blood harbored FKS hot spot mutations (conferring
amino acid substitutions F659-DEL and S663FL630Q).
FIG 2 Pie charts displaying species distributions in the indicatedgroups.N,numberof isolates. Blood isolates representedbaseline colonization inpatients subsequently
exposed to either azoles or echinocandins. Oral isolates (7 days of exposure) represented end-of-treatment colonization. NS, not significant. On the patient level (pie
charts on the samehorizontal level), only the specieswith thehighestECOFFvaluewas counted in caseofpolyfungal samples; however, thedistributionof all oral isolates
is also shown (above for azoles and below for echinocandins). Proportion analysis was performed by chi-square and Fisher’s exact tests.
TABLE 1 Species distribution for isolates from blood and oral swab samples and numbers of paired isolates sharing similar genotypes
Species
No. (%) of isolates
No. of isolates of same species in
paired blood and swab samples
No. (%) of isolates with
similar genotypesaBlood Swabs
C. albicans 102 (49.8) 84 (38.2) 45b 38 (84.4)
C. dubliniensis 3 (1.5) 8 (3.6) 1 1 (100)
C. glabrata 62 (30.2) 82 (37.3) 56 55 (98.2)
C. krusei 8 (3.9) 11 (5.0) 4 4 (100.0)
C. tropicalis 8 (3.9) 12 (5.5) 3 1 (33.3)
C. parapsilosis 10 (4.9) 3 (1.4) 1 1 (100)
S. cerevisiae 3 (1.5) 12 (5.5) 2 1 (50.0)
Other Candida/yeast species 9c (4.4) 8d (3.6) (1e) NAe
Total 205 (100) 220 (100) 112 101 (90.2)
a Isolates with 5/6 or 6/7 identical MLST alleles or with the same fragment length for the microsatellite-based typing of C. parapsilosis.
b One pair of C. albicans isolates came from one patient’s swab samples from two separate C. glabrata candidemia episodes.
c C. lusitaniae (4), C. guilliermondii (1), C. inconspicua (1), C. neoformans (1), C. utilis (1), and C. pelliculosa (1).
d C. guilliermondii (3), C. kefyr (1), C. lusitaniae (2), C. pulcherrima (1), and Geotrichum candidum (1).
e C. lusitaniae (1); the isolate was not genotyped and thus not counted.
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Only 1 of 47 (2.1%) C. albicans oral isolates, from a patient
exposed to 16 days of fluconazole treatment, was azole resistant,
while 0 of 37 oral isolates from unexposed patients and 0 of 100
blood isolates were resistant. Two of 43 (4.7%)C. albicans isolates
from patients exposed to echinocandins harbored an FKS muta-
tion (causing an F641L or D648V amino acid substitution) and
were micafungin resistant, and one of them had cross-resistance
to anidulafungin (Fig. 3). Both FKS mutants were paired with a
previous isogenic wild-type isolate, and they were derived from
patients who had received 28 and 15 days of caspofungin before
the resistant isolate was obtained (see Table S1 in the supplemen-
tal material). MIC distributions of genetically linked blood and
oral isolates for both C. albicans and C. glabrata displayed MIC
histograms equivalent to those for the overall susceptibility data,
FIG 3 MIC distributions for C. glabrata (left) and C. albicans (right). MICs are given in milligrams per liter. White bars show data for blood isolates, gray bars
are for swab isolates obtained after7 days of exposure to either azoles or echinocandins, and black bars are for swab isolates obtained after7 days of exposure
to either drug class. The rows display MIC distributions for (top to bottom) fluconazole, voriconazole, anidulafungin, and micafungin. The y axis indicates the
number of isolates either from blood (positive) or from swabs (negative).
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which also included isolates solely found in either blood or oral
swabs (see Fig. S1).
MIC data for other Candida species showed that two patients
had persistent C. krusei isolates displaying anidulafungin resis-
tance (MIC of 0.125 mg/liter) in blood and oral swabs. Both iso-
lates harbored the Fks1 L701M substitution (Table 3). No other
Candida species displayed acquired resistance to echinocandins.
Two oral isolates were fluconazole resistant (1 of 8 C. dubliniensis
isolates and 1 of 3 C. parapsilosis isolates), while 1 of 8 C. dublini-
ensis isolates was categorized as intermediate; all of these were
from patients exposed to fluconazole for14 days. In addition, 1
of 8 C. tropicalis isolates from blood and 2 of 12 C. tropicalis oral
isolates displayed trailing phenotypes (partial growth inhibition),
and these 3 isolates were acquired from patients with no informa-
tion on previous fluconazole exposure (Table 3).
DISCUSSION
This study investigated the extent of intrinsic and acquired anti-
fungal resistance of the oral fungal community after antifungal
treatment. Overall, this study presented a large proportion of spe-
cies less susceptible to azoles in the colonizing microbiota (pri-
marily C. glabrata) for patients treated with azoles, as well as high
frequencies of acquired resistance to both azoles and echinocan-
dins among colonizing C. glabrata isolates.
Our findings corroborate previous reports demonstrating in-
creased proportions of intrinsically less azole-susceptible species
(primarily C. glabrata) among invasive (6) as well as colonizing
Candida isolates (7) following azole prophylaxis. In contrast, only
discrete and nonsignificant differences in species distribution
were noted for patients treatedwith echinocandins. Echinocandin
prophylaxis was previously demonstrated to significantly drive
the invasive Candida species toward intrinsically less susceptible
species (mainly C. parapsilosis), but that was shown in regions
where the background prevalence of C. parapsilosis was higher
than that in the current settings (1, 6, 8, 32, 33).
Interestingly, azole treatment resulted in more culture-nega-
tive and fewer polyfungal posttreatment oral cultures than those
from echinocandin-exposed patients, despite the same median
treatment duration of 14 days. Because pretreatment oral swabs
could not be obtained for logistical reasons, we cannot rule out
that more patients treated with fluconazole theoretically might
TABLE 2 Acquired resistance to fluconazole and anidulafungin in C. glabrata isolates from blood and swab samples
Isolate group and parameter
Value for isolatesa
Oral (7 days)b Blood (no exposure) Oral (7 days)
Isolates with exposure to azoles
No. of isolates with fluconazole MIC above BP/total no. of isolates (%) 10/34 (29.4) 3/62 (4.8)0.01 5/48 (10.4)0.05
Fluconazole geometric mean MIC (mg/liter) 10.01 3.660.05 4.830.05
Isolates with exposure to echinocandins
No. of isolates with anidulafungin MIC above BP/total no. of isolates (%) 11/51 (21.6) 3/62 (4.8)0.01 1/31 (3.2)0.05
Anidulafungin geometric mean MIC (mg/liter) 0.053 0.043NS 0.048NS
a Superscript numbers indicate significant P values. NS, not significant. BP, EUCAST clinical breakpoint for resistance.
b Reference column for statistical comparisons. Isolates were exposed to either azole or echinocandins for7 days before a swab was obtained.



























C. dubliniensis Blood 3 0.125–1 NA 0 0.03 NA 0.015–0.03 NA NA 0.008–0.015 NA
Swab 8 0.125–128 NA 1c (12.5) 0.03–4 NA 0.015–0.06 NA NA 0.008–0.06 NA
C. tropicalis Blood 8 0.125–16 NA 1d (12.5) 0.03–4 NA 0.008–0.06 NA 0 0.008–0.03 NA
Swab 12 0.25–128 0.5 2e (16.7) 0.03–4 0.03 0.008–0.06 0.03 0 0.008–0.03 0.015
C. krusei Blood 8 16–128 NA Intrinsic 0.125–2 NA 0.015–0.125 NA 2 (25)g 0.06–0.125 NA
Swab 11 16–128 32 Intrinsic 0.125–2 0.25 0.03–0.125 0.06 2 (18.2)g 0.06–0.25 0.125
S. cerevisiae Blood 2 16 NA NA 0.25–0.5 NA 0.06–0.25 NA NA 0.125 NA
Swab 12 2–16 4 NA 0.06–0.25 0.125 0.03–0.5 0.125 NA 0.06–0.25 0.125
C. parapsilosis Blood 10 0.25–1 0.5 0 0.03 0.03 0.5–1 1 NA 0.5–1 1
Swab 3 0.5–8 NA 1f (33.3) 0.03–0.125 NA 1–1 NA NA 0.5–1 NA
a FLC, fluconazole; VRC, voriconazole; ANI, anidulafungin; MICA, micafungin; NA, not applicable (too few isolates).
b Only applicable if a breakpoint exists (EUCAST breakpoints were used).
c One additional isolate was FLC intermediate, with a MIC of 4 mg/liter. Both patients with these isolates were exposed to fluconazole for14 days.
d Trailing phenotype (50% growth inhibition in entire FLC MIC range) and no information on prophylactic treatment for this patient.
e Trailing phenotype. Both patients received caspofungin monotherapy (14 days). One patient had a genetically similar and susceptible C. tropicalis isolate in blood.
f A C. parapsilosis isolate with an FLC MIC of 8 mg/liter was found in a patient exposed to fluconazole for14 days.
g C. krusei isolates harboring the Fks1 L701M substitution were obtained from 2 persistently colonized patients (same species and genotype in the blood and swab), one treated with
caspofungin for14 days and the other exposed to the following three drugs for7 days: fluconazole, voriconazole, and amphotericin B.
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have been culture negative in the oral cavity before treatment and
thus that subsequent differences were not related to the choice of
antifungal treatment. In our view, however, it is more likely that
azoles clear the colonizing mucosal Candidamicrobiota more ef-
fectively than the echinocandins do. This could be explained
partly by the high protein binding affinity of echinocandins and
the associated lower drug concentrations at the mucosal surfaces.
Another hypothesis for a lower positive rate for echinocandin-
treated patients is that C. glabrata is potentially a more persistent
colonizer (34). Indeed, the dominating species was C. glabrata in
swabs from both azole- and echinocandin-treated patients, de-
spite the different initial species distributions in blood. This would
not explain the prevalence of polyfungal oral swabs, however, and
further studies are thus warranted to evaluate these hypotheses
(10, 30, 35, 36).
One approximation for this study was to interpret the blood
isolates as surrogate markers for baseline colonization and to
compare this to subsequent oral colonization. Genotyping re-
vealed a 90% genetic correlation for species acquired from both
sites, supporting the general concept that the invasive species was
also a colonizing agent, as previously shown (15, 37–40). In addi-
tion, the MIC data for paired blood and oral isolates mirrored
those for the overall isolate collection for both C. albicans and C.
glabrata. The stronger genetic association betweenC. glabrata iso-
lates from blood and oral isolates provided more support for the
assumption of C. glabrata as a highly persistent colonizer, but this
could potentially be ascribed to a less discriminatory MLST
scheme (34, 41). In contrast to the findings for C. albicans, where
most isolates had unique genotypes, identical genotypes were
found forC. glabrata isolates, despite no geographical or historical
link, but again, this can probably be ascribed to the low discrimi-
natory power rather than to clonal expansion (41, 42).
The Fks substitutions found inC. glabratawere all well-known
and previously associated with echinocandin resistance (18). The
observed differential susceptibility to echinocandins found here
forC. glabrata has been described previously, with some FKSmu-
tations conferring resistance to anidulafungin but not tomicafun-
gin (43, 44). The observed resistance figures were higher than
those reported from surveillance studies, where 5% acquired
resistance has generally been observed (1, 5, 45–47). However,
acquired echinocandin resistance rates of 10 to 30% have been
reported for C. glabrata upon echinocandin exposure at certain
centers, and depending on the site of infection (10, 48–50). Like-
wise, fluconazole resistance rates ranged from 13.7% in cancer
patients (49) to 33.3% in candidemia patients (6) and 40% in
the colonizing microbiota (7) of patients with previous exposure
to azoles. Our study suggests that even in a nationwide study of
unselected candidemic patients from district as well as university
hospitals, acquired azole and echinocandin resistance in C.
glabrata is common and therefore adds to the concerns that this
organism is becoming an important “multidrug-resistant” yeast
challenge of our time (51–53).
In contrast, the resistance rates among colonizing C. albicans
and other Candida species remained low in exposed patients and
equivalent to resistance rates from surveillance studies (1). Still, as
supported by genotyping, the observed acquisition of azole or
echinocandin resistance is probably an example of in vivo resis-
tance selection upon antifungal exposure, as demonstrated previ-
ously (12, 54).
Our study has several limitations. Ideally, initial oral swabs
from all patients should have been included as a baseline compar-
ator, yet logistically this would require that every patient at risk of
candidemia be sampled whenever blood is cultured. This is a
much more comprehensive, if not impossible, task. Moreover,
ideally, any prior exposure to antifungals unrelated to the treat-
ment of the index candidemia case should have been recorded.
However, despite these limitations, the current systematic study
provides a new understanding of the level of resistance following
treatment which constitutes a reservoir for future resistant Can-
dida infections (15, 16). Together with previous reports of emerg-
ing resistance, our data highlight that the risk of generating anti-
fungal resistance should not be neglected and underscore the
importance of antifungal stewardship and of susceptibility testing
not only for epidemiological purposes but also for daily clinical
management.
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